Coherus Bioscien. Stock
€1.85
Your prediction
Coherus Bioscien. Stock
Pros and Cons of Coherus Bioscien. in the next few years
Pros
Cons
Performance of Coherus Bioscien. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Coherus Bioscien. | -2.030% | -5.846% | -12.181% | -74.111% | -37.747% | -84.738% | -85.192% |
| Ardelyx Inc. | 0.910% | -2.116% | -15.296% | 40.514% | 4.048% | -12.204% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | 2.315% | -15.000% | -67.971% | -20.360% | -98.187% | -99.994% |
| Brainstorm Cell | 1.170% | -1.874% | -1.485% | -81.975% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Coherus, a company in the Biotechnology & Medical Research industry, appear to be experiencing some difficulties. The company has been consistently recording negative net income, alongside an increasing negative total stockholder equity. However, further analysis is required to thoroughly understand the financial health of Coherus.
Growing Revenue: Coherus has experienced a growth in revenue over the past few years. The total revenue increased from $475.8 million in 2020 to $326.6 million in 2021, and continued on an upward trajectory for the first quarter of 2023 with $32.4 million.
Improvement in Gross Profit Margin: The company managed to improve its gross profit margin, which is an indicator of its efficiency in production. For example, the gross profit margin increased from 92.1% in 2020 to 82.4% in 2021.
Comments
News
Why Coherus Biosciences Stock Tumbled on Thursday
The final set of results for Coherus Biosciences' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock
Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.
In a press release
Why Coherus BioSciences Stock Is Sinking Today
Shares of Coherus BioSciences (NASDAQ: CHRS) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling